DOCSLIB.ORG

Glaucoma Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glaucoma Medications 9/5/2020 Glaucoma Pharmacology: Old, New and What to Do? Joseph Sowka, OD Greg Caldwell, OD Rho-Kinase White 1 2 GLAUCOMA EPIDEMIOLOGY AND AQUEOUS HUMOR DYNAMICS TREATMENT IOP – A Complex Homeostasis Current Medical Treatments for OAG Aqueous formation in ciliary body – passive diffusion, ultrafiltration and active secretion Cornea Aqueous Production Aqueous Outflow Conventional Outflow – Trabecular Meshwork → Schlemm’s Canal → Conventional Unconventional Episcleral Venous System Trabecular Meshwork Prostaglandin Non-Conventional Outflow – Schlemm’s -blocker Cholinergic agonist analog Uveoscleral Canal Episcleral CAI NO-donating PGA NO-donating Veins 2-agonist RhoKinase inhibitor PGA 2-agonist Uveoscleral Outflow Updated 1/7/18 Ciliary Processes 3 4 PROSTAGLANDINS: PROSTAGLANDINS OCULAR ADVERSE EFFECTS ▪ Prostaglandins are not indicated ideal in secondary inflammatory glaucoma or any ▪ Hyperemia clinical entity that has anterior segment ▪ Increased iris coloration inflammation as a component ▪ Periorbitopathy: skin darkening, Sulcus ▪ Prostaglandins are important in that they deepening flatten the diurnal IOP curve as well as giving - Hyperemia is reversible with medication cessation. Iris color lingering IOP reduction even as much as 60 changes appear to be irreversible. Periorbitopathy may be reversible if the medication is stopped soon enough, but may hours after dosing. Thus, they are more indeed be permanent. forgiving of patients that miss dosages. ▪ Hypertrichosis ▪ Punctate keratopathy, dry eye ▪ Uveitis, CME, and dendritic keratitis? 5 6 1 9/5/2020 • Xalatan® (latanaprost 0.005%) – Generic latanoprost…APPROVED 3-22-2011 • Travatan-Z® (travoprost 0.004%) – Preserved with Sofzia • Lumigan® (bimatoprost 0.01%) • Zioptan ® (tafluprost 0.0015%)- Merck – Preservative free • Vyzulta™ (latanoprostene bunod 0.024%) – Approved 11/2/17 – NO donating PGA 7 8 9 10 VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) • First prostaglandin analog with one of its metabolites being nitric oxide (NO) • QD dosing • Dual mechanism of action – metabolizes into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm's canal. – Blocks RhoKinase and calcium signaling 11 12 2 9/5/2020 Sorting out the prostaglandins: The XLT study • The first study performed that simultaneously Results of Meta-Analyses of Studies Assessing the compared the clinical outcomes associated Comparative Efficacy of Prostaglandin Analogs with the use of latanoprost, bimatoprost, and travoprost • Compared not only the effectiveness of IOP reduction of the three medications, but also examined the adverse effects and tolerability of the medications Parrish R, Palmberg P, Sheu WP, and the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and pressure: A 12-week, randomized, differences. Surv Ophthalmol. 2008 Nov;53 Suppl1:S69-84. masked-evaluator multicenter study. Am J Ophthalmology 2003; 135 (5):688-703 13 14 The XLT study “Great, but can you tell me something • IOP was significantly reduced from baseline for all that maybe I didn’t already know?” three medications. – Magnitude of the reduction was not statistically significant between the medications • There was no significant difference between the medications in the persistence of pressure lowering or for the mean diurnal pressure throughout the study 15 16 PGA in Chronic Angle Closure Glaucoma • Mechanism is unknown, but results are impressive PGA for chronic angle closure • Aqueous may gain access to CB face/ is an exceptional therapeutic uveoscleral meshwork via still open part of option. angle- or another pathway unknown • PGA have demonstrated pronounced effect in Remember that LPI still needs eyes even with complete PAS angle closure to be performed. –May decrease IOP through uveoscleral tissues other than ciliary face Kook MS et al. Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary body face. A preliminary study. J Oc Pharm and Therapeutics; 2005; 21(1):75-84 17 18 3 9/5/2020 Autonomics Sympathetics • Alpha 1 • Sympathetic Agents – Blood vessels of ciliary body: vasoconstriction, which reduces blood – Adrenergic agonists flow and aqueous production. – Sympathomimetic – Epinephrine-like drugs – Norepinephrine based – Adrenergic antagonist • Alpha 2 – Sympatholytic – Nerve terminal • Beta 1 • Parasympathetic Agents – Heart: increased – Parasympatomimetics • Beta 2 – Cholinergic agonists – Lungs: relaxed- increased breathing ability – acetylcholine based • Beta 1 & 2 on ciliary body – miotics – Stimulation increases aqueous production – Blocking B1 & 2 receptors reduces aqueous production • Beta blockers 19 20 Parasympathetics Parasympathetics • Iris: miosis • Glands: increased activity • Ciliary body: accommodation and trabecular meshwork • Heart: reduced activity opening • Blood vessels: vasodilation • Trabecular meshwork: aqueous outflow increase • Lung: bronchiole constriction • Because these organs are more controlled by the sympathetic system, • Ciliary meshwork (uveal meshwork-uveoscleral pathway)- there is less systemic affects by parasympathomimetic drugs than would aqueous outflow decrease be expected. • Gastrointestinal tract: increased motility • Urinary tract: increased motility 22 23 Adrenergic Agonists: Adrenergic Agonists: 24 25 4 9/5/2020 Alpha-2 agonists Alpha-2 agonists • Brimonidine acts presynaptically to inhibit release of • The most significant side effects are drowsiness and fatigue, norepinephrine and reduces adrenergic receptor stimulation. The reduced sympathetic activity in headache, and dry mouth ciliary body reduces aqueous production. • Other side effects: – Some increase in uveoscleral outflow – Conjunctivitis (follicular), Blurring, Burning • TID dosing • Early and late onset Alphagan allergy – Often used initially BID. – BID dosing can leave the patient with uncontrolled IOP at certain times of the day. • This is significant for monotherapy – Patients on polytherapy may be able to get away with BID dosing 26 27 Brimonidine “Great, but can you tell me something that maybe I didn’t already know?” • No effect on blood pressure, pulse, or pulmonary function – Minimal cardiovascular and pulmonary responses- not frankly contraindicated in patients with cardiovascular disease, but use caution in patients with ischemic heart disease or prior MI • Concurrent use of MAO inhibitors (anti- depressants) are a contraindication to the use of Alphagan • Does not appear to have IOP lowering effects at night/during sleep 28 29 Brimonidine Beta Blockers • Crosses blood-brain barrier and has CNS effects • Adverse effects are most significant in smaller patients and children • This medication has induced fatigue, drowsiness and even coma in children • Contrary to what you might have heard, Alphagan is not proven neuroprotective 30 31 5 9/5/2020 Beta Blockers: Contraindications Beta Blockers: Adverse Effects • Asthma • Bradycardia: • Emphysema – Slowing of sinus nodal discharge with resultant dose- • Myasthenia gravis dependent bradycardia. In most cases, the degree of – Can worsen myasthenia gravis bradycardia is asymptomatic and does not impact a • Cerebrovascular insufficiency patient’s life. • Greater than 1st degree heart block • Patients using topical beta blockers who develop • Hypotension (<100/60) symptomatic bradycardia -- as manifested by • Beta blockers are bad for athletes as it prevents heart rate diminished capacity for physical activity or from exceeding 135 BPM. Athletes cannot train through this undiagnosed syncope -- likely have coexistent block. pathology of the sinus AV node or conduction • Every patient considered for a topical beta blocker needs pathways and should be referred to a cardiologist. baseline blood pressure and resting pulse measurement in addition to review of medical history. – Problem is not likely solely due to beta blockers 32 33 Beta Blockers Beta Blockers • Topical beta blocker therapy should be avoided in • The most significant contraindications are COPD, patients with asymptomatic bradycardia and heart asthma, emphysema, symptomatic bradycardia, block. and asymptomatic bradycardia with heart block. – Patients with symptomatic bradycardia often present with • Beta blockers can be considered in patients with syncope and dizziness, and are identified prior to CHF pending approval by the patient’s PCP. All ophthalmic examination. other contraindications can be considered • Asymptomatic patients without aerobic conditioning ‘relative’ and beta blockers can be used in many (i.e., athletes) with resting pulse rate under 55 beats per of these situations on a case-by-case basis. minute should be evaluated by a cardiologist. • If a ‘contraindication’ is present, it doesn’t mean – However, patients with normal resting pulse rates and with that beta blockers (or any medication for that no history of syncope or dizziness are unlikely to experience matter) cannot be used, but should be a lesser any serious bradycardia effects from topical beta blockers. choice. 34 35 Beta Blockers • Timoptic® (timolol maleate 0.25% & 0.5%) • Timoptic-XE® (timolol maleate gel-forming solution) • Istalol® (timolol maleate 0.5%) • Betimol® (timolol hemihydrate 0.5%) • Betagan®
Load more

Recommended publications
  • Simbrinza BID Adjunctive to PGA Additive Effect of Twice Daily
    Alcon - Business Use Only Effective Date: 30-Mar-2017 Document: TDOC-0050474 Version: 3.0; Most-Recent; Effective; CURRENT Status: Effective Page 1 of 66 a Novartis company Short Title Simbrinza BID Adjunctive to PGA Long Title Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue TDOC-0050474 Version 1.0 replaces TDOC-0018786 Version 1.0 (11-Mar-2015) Protocol Number: GLH694-P001 / NCT02419508 Study Phase: 4 Sponsor Name and Alcon Research, Ltd. Address: 6201 South Freeway Fort Worth, Texas 76134-2099 Investigational Product: SIMBRINZA™ Brinzolamide 1%/Brimonidine 0.2% tartrate ophthalmic suspension US IND# / EudraCT 2015-000736-15 Indication Studied: Ocular Hypertension Open Angle Glaucoma Printed By : Print Date: Alcon - Business Use Only Effective Date: 30-Mar-2017 Document: TDOC-0050474 Version: 3.0; Most-Recent; Effective; CURRENT Status: Effective Page 2 of 66 Investigator Agreement: I have read the clinical study described herein, recognize its confidentiality, and agree to conduct the described trial in compliance with Good Clinical Practices (GCP), the ethical principles contained within the Declaration of Helsinki, this protocol, and all applicable regulatory requirements. Additionally, I will comply with all procedures for data recording and reporting, will permit monitoring, auditing, and inspection of my research center, and will retain all records until notified by the Sponsor. Principal Investigator: Signature Date Name: Address: Printed By : Print Date: Alcon - Business Use Only Effective Date: 30-Mar-2017 Document: TDOC-0050474 Version: 3.0; Most-Recent; Effective; CURRENT Status: Effective Page 3 of 66 1 SYNOPSIS Sponsor: Alcon Research, Ltd.
    [Show full text]
  • Rhopressa™ Netarsudil Ophthalmic Solution 0.02%
    Rhopressa™ Netarsudil ophthalmic solution 0.02% CDER Dermatologic and Ophthalmic Drugs Advisory Committee October 13, 2017 Aerie Pharmaceuticals, Inc. 1 Introduction Marvin Garrett Vice President, Regulatory Affairs and Quality Assurance Aerie Pharmaceuticals, Inc. 2 Aerie Pharmaceuticals • 2005: Aerie founded as a spin-out from Duke University: – Dr. Eric Toone – Dr. Casey Kopczynski – Dr. David Epstein – Dr. Epstein’s goal from the beginning: Develop a therapy that targeted the diseased tissue in glaucoma, the trabecular outflow pathway • 2006: Aerie discovered its first Rho kinase inhibitor • 2009: Aerie invented netarsudil • 2012: Netarsudil 1st clinical study • 2017: NDA filed 3 Netarsudil: A New Drug Class for Lowering IOP We are requesting a recommendation for approval of netarsudil ophthalmic solution 0.02% for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension given one drop QD 4 Agenda Unmet Medical Needs Richard A. Lewis, MD Chief Medical Officer Aerie Pharmaceuticals, Inc. Past President, American Glaucoma Society Program Design and Efficacy Casey Kopczynski, PhD Chief Scientific Officer Aerie Pharmaceuticals, Inc. Safety Theresa Heah, MD, MBA VP Clinical Research and Medical Affairs Aerie Pharmaceuticals, Inc. Benefits and Risks Janet Serle, MD Professor of Ophthalmology Glaucoma Fellowship Director Icahn School of Medicine at Mount Sinai 5 List of Expert Responders • Cynthia Mattox, MD – Associate Professor of Ophthalmology, Tufts University School of Medicine – Current President, American Glaucoma Society • Mark Reasor, PhD – Professor of Physiology & Pharmacology, Robert C. Byrd Health Sciences Center, West Virginia University • Bennie H. Jeng, MD – Professor and Chair, Department of Ophthalmology & Visual Sciences, University of Maryland School of Medicine • Dale Usner, PhD – Biostatistics Consultant to Aerie Pharmaceuticals, Inc.
    [Show full text]
  • Association Between Topical Beta-Blockers and Risks
    BMJ Open: first published as 10.1136/bmjopen-2019-034361 on 22 July 2020. Downloaded from PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. ARTICLE DETAILS TITLE (PROVISIONAL) Association between Topical Beta-Blockers and Risks of Cardiovascular and Respiratory Disease in Glaucoma Patients: a retrospective cohort study AUTHORS Chen, Hsin-Yi; Huang, Wei-Cheng; Lin, Cheng-Li; Kao, Chia-Hung VERSION 1 – REVIEW REVIEWER Marques-Neves, Carlos Ophthalmology University Clinic Faculdade de Medicina da Universidade de Lisboa REVIEW RETURNED 27-Oct-2019 GENERAL COMMENTS Some variables are difficult to control nevertheless, the point is achieved. REVIEWER Reza Razeghinejad Wills Eye Hospital, Philadelphia, PA REVIEW RETURNED 12-Nov-2019 http://bmjopen.bmj.com/ GENERAL COMMENTS A retrospective study on association between Topical Beta- Blockers and Risks of Cardiovascular, stroke, and Respiratory Diseases in Glaucoma Patients reporting higher rate of respiratory issues and stroke in those on beta-blockers. The reported correlations are valid under one condition, being on beta-blocker when the event (stroke, respiratory issues,…..) occurred. The major issue is not including the severity of the systemic diseases and also the severity of glaucoma. on September 25, 2021 by guest. Protected copyright. Although the frequency of DM, HTN, asthma,… were similar between both group, there is no data on the severity of these diseases, for example if the HbA1c of those taking beta blockers is higher it could be the cause of higher rate of stroke not the beta- blockers.
    [Show full text]
  • Drug Class Review Ophthalmic Cholinergic Agonists
    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
    [Show full text]
  • The Eyes Have It! Update on Common Conditions Affecting the Eye
    Pharmacy Tech Topics™ VOLUME 22 NO. 2 | APRIL 2017 The Eyes Have It! Update on Common Conditions Affecting the Eye AUTHORS: Steven R. Abel, BS Pharm, PharmD, FASHP Kirk Evoy, PharmD, BCACP, BC-ADM, TTS PEER REVIEWERS: Sami Labib, RPh Rita Edwards, CPhT EDITOR: Patricia M. Wegner, BS Pharm, PharmD, FASHP DESIGN EDITOR: Leann Nelson Pharmacy Tech Topics™ (USPS No. 014-766) is published quarterly for $50 per year by the Illinois Council of Health-System Pharmacists, 4055 N. Perryville Road, Loves Park, IL 61111-8653. Phone 815-227-9292. Periodicals Postage Paid at Rockford, IL and additional mailing offices. POSTMASTER: Send address changes to: Pharmacy Tech Topics™, c/o ICHP, 4055 N. Perryville Road, Loves Park, IL 61111-8653 COPYRIGHT ©2017 by the Illinois Council of Health-System Pharmacists unless otherwise noted. All rights reserved. Pharmacy Tech Topics™ is a trademark of the Illinois Council of Health-System Pharmacists. This module is accredited for 2.5 contact hours of continuing pharmacy education and is recognized by the Pharmacy Technician Certification Board (PTCB). Cover image property of ©2017 Adobe Stock. LEARNING OBJECTIVES Upon completion of this module, the subscriber will be able to: 1. Identify the parts of the eye and the function of each part. 2. Summarize various eye disorders including ocular hypertension, glaucoma, infections, dry eyes, conjunctivitis, age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema. 3. Discuss brand/generic substitutions, possible side effects, and proper administration of ophthalmic medications. 4. Describe the roles of various ophthalmic agents including those used to treat the following conditions: ocular hypertension, glaucoma, infections, dry eyes, conjunctivitis, age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.
    [Show full text]
  • Personalized Glaucoma Medication Compounding Reduces Intraocular Pressure and May Increase Adherence and Affordability
    Laroche D, et al., J Ophthalmic Clin Res 2021, 8: 085 DOI: 10.24966/OCR-8887/100085 HSOA Journal of Ophthalmology & Clinical Research Case Report leading cause of blindness worldwide [1]. The exact etiology of the Personalized Glaucoma degenerative damage to the optic nerve seen in glaucoma is multifac- torial, and risk factors include older age, increased cup-to-disc ratio Medication Compounding of the optic nerve, a thin central cornea, family history, and increased Intraocular Pressure (IOP) [2]. IOP is the only known modifiable risk Reduces Intraocular Pressure factor; the greater the IOP, the faster damage progresses. Glaucoma treatment is therefore focused on reducing IOP through surgery, laser, and May Increase Adherence and or pharmacological therapy, and medications are generally the first step. While the initial approach to adult glaucoma is often surgical Affordability and often involves early cataract extraction to lower IOP and accom- Daniel Laroche1,3*, Elise Mike2 and Chester Ng3 panying angle surgery to restore outflow via Schlemm’s canal, some 1New York Eye and Ear Infirmary, Icahn School of Medicine of Mount Sinai, patients refuse or fail surgery and require multiple medications for New York, NY, USA disease management. Often, more than one medication is needed to 2Albert Einstein College of Medicine, Bronx, NY, USA meet and maintain the target IOP, and effectiveness of treatment is 3Advanced Eye care of New York, NY, USA limited by treatment adherence [3]. Medications also have the active ingredients and preservatives that can lead to ocular erythema and Abstract conjunctivitis, further reducing compliance [4]. Compounding mul- tiple topical agents into a single solution has several benefits when Glaucoma treatment relies on Intraocular Pressure (IOP) reduc- tion through surgical or pharmacological means.
    [Show full text]
  • Brimonidine/Timolol Versus Dorzolamide/Timolol and Various Two-Bottle Combinations Gail F
    perim Ex en l & ta a l ic O p in l h t C h Schwartz et al. f Journal of Clinical & Experimental a , J Clin Exp Ophthalmol 2012, 3:8 o l m l a o n l DOI: 10.4172/2155-9570.1000248 r o g u y o J Ophthalmology ISSN: 2155-9570 ResearchResearch Article Article OpenOpen Access Access Adherence and Persistence with Glaucoma Therapy: Brimonidine/Timolol versus Dorzolamide/Timolol and Various Two-Bottle Combinations Gail F. Schwartz1,2*, Caroline Burk3, Teresa Bennett4 and Vaishali D. Patel5 1Greater Baltimore Medical Center, Baltimore, MD, USA 2Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA 3Health Outcomes Consultant, Laguna Beach, CA, USA 4Source Healthcare Analytics, Phoenix, AZ, USA 5Allergan, Inc., Irvine, CA, USA Abstract Purpose: Patients with glaucoma often require multiple topical medications to reach target intraocular pressure. This database analysis examined persistence and adherence in patients’ prescribed fixed-combination brimonidine/ timolol, fixed-combination dorzolamide/timolol, or various commonly used two-bottle combinations. Participants: Glaucoma patients (ICD-9 code: 365.xx; n=7883) from the Source Healthcare Analytics Source® Lx database with an index prescription for fixed-combination brimonidine/timolol, fixed-combination dorzolamide/timolol, or various commonly used two-bottle combinations during the 6-month qualifying period (January 2008–June 2008), but not the 12 months before, were included. Methods: In this retrospective prescription database analysis, adherence and persistence for fixed- combination brimonidine/timolol were compared to fixed-combination dorzolamide/timolol and various commonly used two-bottle combinations. The two-bottle arms were: β-blocker+brimonidine; β-blocker+carbonic anhydrase inhibitor; β-blocker+prostaglandin analogue; carbonic anhydrase inhibitor+brimonidine; carbonic anhydrase inhibitor+prostaglandin analogue; and prostaglandin analogue+brimonidine.
    [Show full text]
  • Primary Open-Angle Glaucoma Preferred Practice Pattern®
    Primary Open-Angle Glaucoma Preferred Practice Pattern® P71 Secretary for Quality of Care Timothy W. Olsen, MD Academy Staff Ali Al-Rajhi, PhD, MPH Andre Ambrus, MLIS Meghan Daly Flora C. Lum, MD Medical Editor: Susan Garratt Approved by: Board of Trustees September 12, 2020 Copyright © 2020 American Academy of Ophthalmology® All rights reserved AMERICAN ACADEMY OF OPHTHALMOLOGY and PREFERRED PRACTICE PATTERN are registered trademarks of the American Academy of Ophthalmology. All other trademarks are the property of their respective owners. Preferred Practice Pattern® guidelines are developed by the Academy’s H. Dunbar Hoskins Jr., MD Center for Quality Eye Care without any external financial support. Authors and reviewers of the guidelines are volunteers and do not receive any financial compensation for their contributions to the documents. The guidelines are externally reviewed by experts and stakeholders before publication. P72 Primary Open-Angle Glaucoma PPP GLAUCOMA PREFERRED PRACTICE PATTERN® DEVELOPMENT PROCESS AND PARTICIPANTS The Glaucoma Preferred Practice Pattern® Panel members wrote the Primary Open-Angle Glaucoma Preferred Practice Pattern® guidelines (PPP). The PPP Panel members discussed and reviewed successive drafts of the document, meeting in person twice and conducting other review by e-mail discussion, to develop a consensus over the final version of the document. Glaucoma Preferred Practice Pattern Panel 2019-2020 Steven J. Gedde, MD, Chair Kateki Vinod, MD Martha M. Wright, MD, American Glaucoma Society Representative Kelly W. Muir, MD John T. Lind, MD Philip P. Chen, MD Tianjing Li, MD, MHS, PhD, Consultant, Cochrane Eyes and Vision Project Steven L. Mansberger, MD, MPH, Methodologist We thank our partners, the Cochrane Eyes and Vision US Satellite (CEV@US), for identifying reliable systematic reviews that we cite and discuss in support of the PPP recommendations.
    [Show full text]
  • Ophthalmic Drugs
    A Supplement to 22nd EDITION Randall Thomas, OD, MPH Patrick Vollmer, OD The Clinical Guide to Dr. Melton Ophthalmic[ [ Dr. Thomas Drugs Dispense as writ ten — no substit utions. Refills: unlimit ed. May 15, 2018 Dr. Vollmer Peer-to-peer advice to help boost your prescribing prowess. Supported by an unrestricted grant from Bausch + Lomb 001_dg0518_fc.indd 3 5/11/18 10:52 AM FROM THE AUTHORS DEAR OPTOMETRIC COLLEAGUES: Supported by an Welcome to the 2018 edition of our annual Clinical Guide to Ophthalmic unrestricted grant from Drugs. Herein, we provide updates on our collective clinical experiences and Bausch + Lomb heavily season them with pertinent excerpts from the literature. This guide is intended to bring solid, scientifically accurate and clinically relevant information to our optometric colleagues. If you want to understand CONTENTS how the three of us treat, and what factors led us to develop these methods, you’ll find it explained here. The methods and opinions represented are our own. We recognize that other doctors may use alternative approaches. That First-year Impressions ...........3 is true in all of health care. But this three-doctor writing team has logged over 75 combined years of clinical optometry, and we bring that ‘real-world’ spirit to the discussions that follow. Know that, above all, we are doctors who are genuinely concerned for our patients’ well-being and who endeavor to Glaucoma Care .......................... 6 provide them the best of care, and we write from that perspective. The two topics of greatest interest and need for most eye physicians right now are glaucoma and dry eye disease.
    [Show full text]
  • Understanding and Living with Glaucoma
    Understanding and Living with Glaucoma Betty hopes future generations won’t have to live with glaucoma. Dr. Goldberg’s breakthrough research could mean they won’t have to. Understanding and Living with Glaucoma C SUPPORTED BY AN EDUCATIONAL GRANT FROM AERIE PHARMACEUTICALS, INC. Glaucoma is an eye disease that gradually steals your vision. Usually, glaucoma has no symptoms in its early stages. But without proper treatment glaucoma can lead to blindness. The good news is that with regular eye exams, early detection, and treatment, you can preserve your sight. This guide will give you a complete introduction to the facts about glaucoma. D Glaucoma Research Foundation 2 INTRODUCTION 3 UNDERSTANDING GLAUCOMA 3 Understand the Eye to Understand Glaucoma 4 How Glaucoma Affects the Eye 6 Who Gets Glaucoma? 7 Are There Symptoms? 7 When Should You Get Your Eyes Checked for Glaucoma? 8 DIFFERENT TYPES OF GLAUCOMA 8 Primary Open-Angle or Open-Angle Glaucoma 9 Primary Angle-Closure or Angle-Closure Glaucoma or Narrow-Angle Glaucoma 10 Other Types of Glaucoma 10 • Normal-Tension Glaucoma 10 • Secondary Glaucoma 12 DETECTING GLAUCOMA 12 How Is Glaucoma Diagnosed? 12 What To Expect During Glaucoma Examinations 12 • Tonometry 12 • Ophthalmoscopy 15 • Perimetry 16 • Gonioscopy 16 • Pachymetry 17 TREATING GLAUCOMA 17 Treatment of Primary Open-Angle Glaucoma 17 • Selective Laser Trabeculoplasty 18 • Glaucoma Medications 21 • Incisional Surgeries 25 • Unapproved Treatments 25 Treatment of Primary Angle-Closure Glaucoma 26 Treatment of Other Types of Glaucoma 28 FREQUENTLY ASKED QUESTIONS 30 LIVING WITH GLAUCOMA 30 Working with Your Doctor 32 Responding to Vision Changes Due to Glaucoma 32 Questions For Your Doctor 34 Your Lifestyle Counts 35 Looking Ahead 36 APPENDIX 36 A Guide To Glaucoma Medications 38 Glossary Understanding and Living with Glaucoma 1 Introduction If you have been diagnosed with glaucoma, or are a glaucoma suspect, you probably have a lot of questions and some concerns.
    [Show full text]
  • Travatan, INN-Travoprost
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Travatan. This scientific discussion has been updated until 1 November 2003. For information on changes after this date please refer to module 8B. 1. Introduction Travoprost is a prostaglandin analogue intended for use to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The product is presented in a concentration of 40 µg/ml of preserved eye drops (0.004%). The dose is one drop of Travoprost Eye Drops in the conjunctival sac of the affected eye(s) once daily. Travoprost Eye Drops contains travoprost (AL- 6221), a prostaglandin analogue, in a sterile ophthalmic solution formulation and it is a selective, full agonist for the FP prostanoid receptor. FP receptor agonists are reported to reduce IOP by increasing uveoscleral outflow. Rationale for the product Glaucoma is the leading cause of irreversible blindness in the world. It is a frequent disease and it has been estimated that 66.8 million have glaucoma, 6.7 million of whom are bilaterally blind. Open angle glaucoma is the most common type, mainly primary but also, in some cases, open angle glaucoma is secondary to the exfoliation syndrome or other primary ocular diseases. Glaucoma is an optic neuropathy that leads to loss of optic-nerve tissue with an excavation of the ophthalmoscopically visible optic nerve head and consequently, to a progressive loss of vision. The elevated IOP is the main risk factor for its development and reduction of IOP has been demonstrated to protect against further damage to the optic nerve, even in patients with IOP that is statistically "normal" (so called normal tension glaucoma).
    [Show full text]
  • Periorbital Dermatitis As a Side Effect of Topical Dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell
    378 SCIENTIFIC CORRESPONDENCE Br J Ophthalmol: first published as 10.1136/bjo.86.4.378 on 1 April 2002. Downloaded from Periorbital dermatitis as a side effect of topical dorzolamide Y M Delaney, J F Salmon, F Mossa, B Gee, K Beehne, S Powell ............................................................................................................................. Br J Ophthalmol 2002;86:378–380 Aim: To report periorbital dermatitis as a late side effect of topical dorzolamide hydrochloride (Trusopt), a drug used to reduce intraocular pressure. Methods: A retrospective study of 14 patients who devel- oped periorbital dermatitis while using topical dorzola- mide hydrochloride was undertaken. Six patients underwent patch testing for sensitivity to Trusopt, dorzola- mide hydrochloride, and the preservative benzalkonium chloride. Results: The periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing dorzolamide hydro- β chloride therapy. 13 patients had used preserved topical Figure 1 Case 14. Marked dermatitis of the left lower lid and blocker treatment for a mean period of 34.2 months with- periorbital area, which resolved on discontinuing topical out complication before the introduction of dorzolamide. In dorzolamide. eight (57.1%) the dermatitis resolved completely after dis- continuing dorzolamide but in six (42.9%) resolution of the dermatitis did not occur until the concomitant preserved β blocker was stopped and substituted with preservative free drops. Patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and benzalkonium chloride was negative. Conclusion: These findings suggest that dorzolamide can cause severe periorbital dermatitis. Although the dermatitis may resolve when dorzolamide is discontinued, this does http://bjo.bmj.com/ not always occur and in some patients all topical medication containing benzalkonium chloride needs to be stopped.
    [Show full text]